Omeros Co. (NASDAQ:OMER) Short Interest Down 16.9% in November

Omeros Co. (NASDAQ:OMER) saw a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 8,920,000 shares, a decline of 16.9% from the November 15th total of 10,730,000 shares. Approximately 16.1% of the shares of the stock are short sold. Based on an average trading volume of 701,200 shares, the short-interest ratio is presently 12.7 days.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on OMER shares. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Thursday, November 14th. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Rodman & Renshaw began coverage on Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective for the company. Finally, RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Omeros presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Omeros Stock Down 10.1 %

OMER stock opened at $7.63 on Monday. The stock has a market capitalization of $442.16 million, a price-to-earnings ratio of -3.30 and a beta of 1.97. The stock’s fifty day simple moving average is $6.61 and its 200-day simple moving average is $5.01. Omeros has a 52-week low of $2.61 and a 52-week high of $12.65.

Institutional Trading of Omeros

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP acquired a new stake in shares of Omeros in the third quarter worth approximately $305,000. Barclays PLC grew its stake in shares of Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 51,873 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after buying an additional 31,081 shares during the last quarter. AQR Capital Management LLC purchased a new position in shares of Omeros in the 2nd quarter worth $105,000. Finally, SG Americas Securities LLC acquired a new position in Omeros in the third quarter valued at $80,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.